Nothing Special   »   [go: up one dir, main page]

SI1608362T1 - Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino - Google Patents

Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Info

Publication number
SI1608362T1
SI1608362T1 SI200330805T SI200330805T SI1608362T1 SI 1608362 T1 SI1608362 T1 SI 1608362T1 SI 200330805 T SI200330805 T SI 200330805T SI 200330805 T SI200330805 T SI 200330805T SI 1608362 T1 SI1608362 T1 SI 1608362T1
Authority
SI
Slovenia
Prior art keywords
active substance
pharmaceutical preparation
stabilized pharmaceutical
amorphous active
amorphous
Prior art date
Application number
SI200330805T
Other languages
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1608362(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Publication of SI1608362T1 publication Critical patent/SI1608362T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200330805T 2002-10-11 2003-10-10 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino SI1608362T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance

Publications (1)

Publication Number Publication Date
SI1608362T1 true SI1608362T1 (sl) 2007-12-31

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
SI200330805T SI1608362T1 (sl) 2002-10-11 2003-10-10 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Country Status (21)

Country Link
US (2) US20040077708A1 (sl)
EP (1) EP1608362B1 (sl)
CN (1) CN100372529C (sl)
AR (1) AR041588A1 (sl)
AT (2) ATE354362T1 (sl)
AU (1) AU2003280361B2 (sl)
CY (1) CY1106608T1 (sl)
CZ (1) CZ17610U1 (sl)
DE (2) DE20321455U1 (sl)
DK (2) DK1608362T3 (sl)
ES (1) ES2285205T3 (sl)
FI (1) FI7617U1 (sl)
ME (1) ME00514B (sl)
PT (1) PT1608362E (sl)
RS (1) RS51819B (sl)
RU (1) RU2358727C2 (sl)
SI (2) SI21302A (sl)
SK (1) SK5233Y1 (sl)
TW (1) TWI320709B (sl)
UA (1) UA85544C2 (sl)
WO (1) WO2004032920A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP4739672B2 (ja) 2001-12-21 2011-08-03 ネクター セラピューティクス 湿気のバリアを有するカプセルパッケージ
SK50462005A3 (sk) * 2003-08-05 2005-09-08 Zentiva, A. S. Spôsoby stabilizácie atorvastatínu
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
WO2006008091A2 (en) 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
WO2006059224A1 (en) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CA3011685C (en) * 2015-02-03 2021-07-20 Kadmon Pharmaceuticals, Llc Stable trientine formulations
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (sl) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
AU3761495A (en) * 1994-09-30 1996-04-26 Becton Dickinson & Company Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
EP1296672B2 (en) * 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
UA85544C2 (ru) 2009-02-10
CN100372529C (zh) 2008-03-05
SK5233Y1 (en) 2009-09-07
DE60312049D1 (de) 2007-04-05
TW200501947A (en) 2005-01-16
FIU20070036U0 (fi) 2007-01-26
SK50062007U1 (en) 2009-03-05
SI21302A (sl) 2004-04-30
RU2358727C2 (ru) 2009-06-20
ATE354362T1 (de) 2007-03-15
CZ17610U1 (cs) 2007-06-18
ES2285205T3 (es) 2007-11-16
EP1608362B1 (en) 2007-02-21
CN1703215A (zh) 2005-11-30
TWI320709B (en) 2010-02-21
WO2004032920A1 (en) 2004-04-22
CY1106608T1 (el) 2012-01-25
FI7617U1 (fi) 2007-09-28
DE60312049T2 (de) 2007-10-04
RS20050273A (en) 2007-06-04
DK200700025U1 (da) 2007-06-08
US20040077708A1 (en) 2004-04-22
AR041588A1 (es) 2005-05-26
AU2003280361A1 (en) 2004-05-04
EP1608362A1 (en) 2005-12-28
ME00514B (me) 2011-10-10
RS51819B (sr) 2011-12-31
PT1608362E (pt) 2007-05-31
US20090012150A1 (en) 2009-01-08
DE20321455U1 (de) 2007-05-24
DK200700025U4 (da) 2008-03-14
DK1608362T3 (da) 2007-05-14
AT10424U1 (de) 2009-03-15
RU2005114485A (ru) 2006-01-27
AU2003280361B2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
SI1608362T1 (sl) Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
AU2003252299A8 (en) Novel physiologically active substance
AU2003280269A1 (en) Device for automatically injecting an active substance
GB0210397D0 (en) Pharmaceutical formulations
PL374390A1 (en) Fungicidal active substance combinations
IL162110A0 (en) Micronized film-forming powder comprising an active substance
IL207028A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
PL374347A1 (en) Solid pharmaceutical formulations comprising telmisartan
PL373806A1 (en) Novel physiolgically active substances
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
EP1548121A4 (en) NEW PHYSIOLOGICALLY ACTIVE SUBSTANCES
EP1604971A4 (en) PROCESS FOR ADDING ACTIVE CHARCOAL IN WATER PURIFICATION AND WATER PURIFICATION METHOD
AU2003300469A1 (en) Methods for making pharmaceutical dosage forms containing active cushioning components
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
GB2392093B (en) Pharmaceutical formulations
AU2003210553A1 (en) Substance delivery device
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
AU2001246389A1 (en) Pharmaceutical kit comprising midodrine as an active drug substance
AU2003233092A1 (en) Improved electro-optically active device
HU0303383D0 (en) Pellets containing active ingredient
GB0219897D0 (en) Pharmaceutically active compounds